Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder in Adults
NCT06547489 is registered in ClinicalTrials.gov with Syndeio Biosciences, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multicenter, Randomized, Double-blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder in Adults
- Lead sponsor
- Syndeio Biosciences, Inc
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 3, 2025
- Completion date
- December 31, 2027
- Enrollment
- 164 (estimated)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.